Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Advances in Natural Killer Cell Therapies for Breast Cancer Publisher Pubmed



Kiaei SZF1 ; Nouralishahi A2 ; Ghasemirad M3 ; Barkhordar M4 ; Ghaffari S5 ; Kheradjoo H6 ; Saleh M7 ; Mohammadzadehsaliani S8 ; Molaeipour Z9
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Pulmonary and Critical Care, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Eye Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
  3. 3. Department of Periodontics, Faculty of Dentistry, Rafsanjan University of Medical Sciences, Rafsanjan, Iran
  4. 4. Hematology, Oncology and Stem Cell Transplantation Research Center (HORCSCT), Tehran University of Medical Sciences, Tehran, Iran
  5. 5. Department of Immunology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
  6. 6. Laboratory Department, Buraimi Hospital, Buraimi, Oman
  7. 7. Wisconsin National Primate Research Center, University of Wisconsin Graduate School, Madison, WI, United States
  8. 8. Ophthalmology Department, Buraimi Hospital, Buraimi, Oman
  9. 9. Hematology Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

Source: Immunology and Cell Biology Published:2023


Abstract

Breast cancer (BC) is the most common cause of cancer death in women. According to the American Cancer Society's yearly cancer statistics, BC constituted almost 15% of all the newly diagnosed cancer cases in 2022 for both sexes. Metastatic disease occurs in 30% of patients with BC. The currently available treatments fail to cure metastatic BC, and the average survival time for patients with metastatic BC is approximately 2 years. Developing a treatment method that terminates cancer stem cells without harming healthy cells is the primary objective of novel therapeutics. Adoptive cell therapy is a branch of cancer immunotherapy that utilizes the immune cells to attack cancer cells. Natural killer (NK) cells are an essential component of innate immunity and are critical in destroying tumor cells without prior stimulation with antigens. With the advent of chimeric antigen receptors (CARs), the autologous or allogeneic use of NK/CAR–NK cell therapy has raised new hopes for treating patients with cancer. Here, we describe recent developments in NK and CAR–NK cell immunotherapy, including the biology and function of NK cells, clinical trials, different sources of NK cells and their future perspectives on BC. © 2023 the Australian and New Zealand Society for Immunology, Inc.
Other Related Docs
16. Immunotherapy a New Hope for Cancer Treatment: A Review, Pakistan Journal of Biological Sciences (2018)
20. Oncolytic Virotherapy Improves Immunotherapies Targeting Cancer Stemness in Glioblastoma, Biochimica et Biophysica Acta - General Subjects (2024)